Eloxx Pharmaceuticals to Host Investor and Analyst Call on Alport Syndrome
Globally renowned Alport syndrome experts will provide key insights
Eloxx recently announced achievement of remission in one patient in its Phase 2 Alport syndrome clinical study and decision to advance into a pivotal trial in Alport syndrome
Related news for (ELOX)
- Eloxx Pharmaceuticals Provides Pipeline and Financing Updates
- Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updates
- Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases
- Eloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business Update
- Eloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business Update